Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Vodefen - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Vodefen

Approved

STANDARD

Vodefen

Mercury Laboratories, Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: b0f11e3bb075b7f9
Company: Mercury Laboratories, Ltd.
Type: Standard

Approval Details

Approval Id: b0f11e3bb075b7f9
Drug Approval Philippines Name: Vodefen
Product Name: Vodefen
Registration Number: DR-XY38791
Brand Name: Vodefen
Generic Name: Diclofenac Potasisum
Dosage Form: Enteric-Coated Tablet
Dosage Strength: 50 mg
Manufacturer: Mercury Laboratories, Ltd.
Importer: Phil Pharmawealth, Inc.
Distributor: Phil Pharmawealth, Inc.
Issuance Date: 26 November 2020
Expiry Date: 25 November 2025
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

b0f11e3bb075b7f9

Type

Standard

Back to Philippines FDA Approvals